GeneDx Holdings (WGS) Operating Expenses (2020 - 2026)

GeneDx Holdings (WGS) has reported Operating Expenses for 7 consecutive years, with $95.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Operating Expenses rose 54.49% year-over-year to $95.7 million in Q2 2026; TTM through Jun 2026 was $332.0 million, a 54.62% increase from a year earlier, with the FY2025 full-year figure at $239.2 million, up 39.17% from the prior year.
• Operating Expenses was $95.7 million for Q2 2026 at GeneDx Holdings, up from $94.4 million in the prior quarter.
• Over five years, Operating Expenses peaked at $104.2 million in Q2 2022 and troughed at $39.5 million in Q1 2024.
• A 5-year average of $65.0 million and a median of $62.5 million in 2025 frame the typical range for Operating Expenses.
• The widest YoY moves for Operating Expenses: up 231.23% in 2022, down 53.39% in 2022.
• Over 5 years, Operating Expenses stood at $72.4 million in 2022, then tumbled by 35.36% to $46.8 million in 2023, then dropped by 2.18% to $45.8 million in 2024, then soared by 61.45% to $74.0 million in 2025, then gained by 29.38% to $95.7 million in 2026.
• The last three Operating Expenses figures came in at $95.7 million (Q2 2026), $94.4 million (Q1 2026), and $74.0 million (Q4 2025), per Business Quant data.